Hematology, immunology and clinical chemistry profiles of COVID-19 patients: Systematic review by Wolde, Mistire
 
 




Hematology, immunology and clinical chemistry profiles of 





Background: COVID-19 is an emerging novel viral infection that first emerged in December 2019 and was 
officially pronounced as a ‘pandemic’ by March 2020. One of the strategies to control the spread of COVID-19 
disease is expanding laboratory diagnosis services. So far, the molecular biology-based real-time polymerase chain 
reaction (RT-PCR) method is the only recommended laboratory test to diagnose the disease. However, during 
COVID-19 infection, hematology, immunology, and clinical chemistry test profile changes might also assist in 
diagnosing the disease.  
Objective: The objective of this systematic review was “assessment of routine hematology, immunology, and 
clinical chemistry test profile changes among COVID-19 RT-PCR laboratory tests positive individuals”, which, 
before such tests are carried out, might suggest the occurrence of COVID-19 infection.  
Material and methods: The systematic review was done to assess general epidemiology, routine clinical chemistry 
and hematology/ immunohematology tests done in association with COVID-19 diagnosed cases. Online published 
articles were searched using PubMed, Hinari, AGORA and Google Scholar search engines, based on the following 
inclusion criteria: articles on COVID-19 that focus on human coronavirus diseases, their epidemiology, laboratory 
diagnosis of such diseases, the RT-PCR test, and additional routine laboratory tests. Exclusion criteria included 
articles that discuss the RT-PCR method only, imaging diagnostic methods, and those that focus on specific 
groups (such as COVID-19 among diabetes patients, cancer patients and so on). Accordingly, a total of 75 
research articles were identified. Of these, 29 papers were selected for systematic review.  
Results: From the collected 29 articles on routine clinical chemistry tests, it was concluded that in confirmed 
COVID-19 cases, aminotransferase enzymes – alanine transaminase (ALT) and aspartate transaminase (AST) – 
bilirubin, creatine kinase (CK), troponin, lactate dehydrogenase (LDH), creatine  and ferritin values were 
relatively high, whereas the albumin value was reduced. In the hematology/immunohematology tests, total white 
blood cell (WBC) counts, neutrophil counts, erythrocyte sedimentation rates (ESR), C-reactive protein (CRP) and 
prothrombin time (PT) increased, whereas lymphocyte counts, platelet counts, and cluster of differentiation 4 
(CD4) and cluster of differentiation 8 (CD8) counts decreased. In addition, neutrophil-lymphocyte (N-L) ratios 
increased, whereas lymphocyte-C-reactive protein (L-C) ratios decreased.  
Conclusions: For those individuals with signs and symptoms of COVID-19, leukocytosis with neutrophilia and 
lymphopenia, high N-L and low L-C ratios, mild increases in aminotransferase and creatinine values with 
increased CK, troponin and ferritin levels, might be considered as “routine laboratory test results that are 
supportive of occurrence COVID-19 disease”. Further large-scale studies are required to strengthen the present 
findings. [Ethiop. J. Health Dev. 2020; 34(3):226-231] 
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Introduction 
Coronaviruses are known viral infections that cause 
different degrees of respiratory tract infection in 
humans. The different human coronavirus (HCoV) 
strains include HCoV-229E, HCoV-NL63, HCoV-
HKU1, HCoV-OC43, Middle East respiratory 
syndrome coronavirus (MERS-CoV), and severe acute 
respiratory syndrome coronavirus (SARS-CoV). 
COVID-19 emerged and was first reported in Wuhan, 
Hubei province, China, in December 2019 (1). The 
disease spread so swiftly across the world, and it was 
formally pronounced as a ‘pandemic’ by March 2020. 
Although COVID-19 has a relatively low mortality 
ratio compared to SARS, due to its very fast 
transmission, it has caused a significant total death toll 
worldwide (2).  
 
Studies show that common signs and symptoms of 
COVID-19 patients include fever (88.7%), cough 
(67.8%), fatigue (38.1%), sputum production (33.4%), 
shortness of breath (18.6%), sore throat (13.9%), 
headache (13.6%), and gastrointestinal symptoms with 
diarrhea (3.8%) and vomiting (5.0%) (3,4). Morbidity 
and mortalities associated with COVID-19 are more 
often associated with elderly patients, and those with 
underlying chronic disease conditions such as 
hypertension, diabetics, asthma and cardiovascular 
diseases (5).  
 
Globally, as of 9:20 am CEST on July 15, 2020, there 
were 13,119,239 confirmed cases of COVID-19, 
including 573,752 deaths, reported to the World Health 
Organization (WHO). So far, the United States of 
America leads the world with 3,344,783 confirmed 
cases and 135,053 deaths (6). In Ethiopia, the first 
COVID-19 case was reported on 13 March 2020 (7). 
As at July 14, 2020, there were 8,181 confirmed cases 
and 146 deaths in the country (8). 
 
To diagnose COVID-19, the laboratory test 
recommended by WHO, Centers for Disease Control 
and Prevention (CDC) and other national and 
international health organizations, and used by many 
reference laboratories worldwide, is the RT-PCR 
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method. This method involves collecting samples 
mainly from nasopharyngeal and oropharyngeal swabs 
of suspected individuals (9). In terms of serological 
tests to detect either SARS-CoV-2 virus antigens or 
antibodies, to the best of the author’s knowledge, there 
is no highly sensitive and specific test kit approved for 
the diagnosis of the disease by any international 
organization, such as WHO or CDC that can be used 
worldwide, including in Ethiopia. On the other hand, 
RT-PCR-based diagnosis is expensive for most 
developing countries and others where technology 
and/or expertise is not available. 
 
Studies indicate that the SARS-CoV-2 virus attaches to 
angiotensin-converting enzyme 2 (ACE2) receptors 
that are found on the surface of different organs and 
system-forming cells of the body, including alveolar 
epithelial cells, intestinal epithelial cells, liver cells, 
and heart, and renal tubules (10). Thus, it is reasonable 
to consider any abnormal findings of metabolic and/or 
organ function tests to be indicative of COVID-19 
disease. Accordingly, the presence of ACE2 receptors 
in specific body parts either creates the opportunity of 
virus attack, or, in association with the respiratory 
system attack of COVID-19 infection or other 
organs/system, results in abnormal biochemical 
profiles of COVID-19 patients. 
 
Moreover, studies show that after individuals have 
acquired SARS-CoV-2, the viral infection leads to 
signs and symptoms of diseases, usually those 
associated with a suppressed immune system, and/or 
the virus creates opportunities for other infectious 
diseases, such as bacterial, attacks, and also disturbs 
the normal hematology and immune-hematology 
profiles of COVID-19-infected individuals (11).  
 
Therefore, the objective of this study was to assess 
routine hematology, immunology, and clinical 
chemistry test profile changes among individuals who 
had tested positive following COVID-19 RT-PCR 
laboratory tests. The suggested routine laboratory tests 
are relatively available in most clinical laboratories, 
results are issued within short periods, and they may 
assist in the management of COVID-19 disease. By 
conducting these auxiliary tests, those patients who 
show results indicating COVID-19 infection can then 
be tested using the RT-PCR test. Restricting the extent 
of RT-PCR testing in this way will save money, as well 
as quickly identify cases in the community.  
 
Material and methods 
Search approach: Different online databases, 
including PubMed, Hinari, AGORA, Google Scholar, 
and as well reported news articles related to COVID-19 
diseases, were examined. Online materials published 
from January 1, 2020 to June 1, 2020 were included in 
the study. The search terms used, separately and in 
combination, included ‘COVID-19 laboratory tests’, 
‘COVID-19 nucleic acid tests’, ‘COVID-19 
epidemiology’, ‘COVID-19 and liver function tests’, 
‘COVID-19 and renal function tests’, ‘COVID-19 and 
cardiac markers’, ‘COVID-19 and hematology tests’ 
and ‘COVID-19 and immunological tests’.  
 
Inclusion and exclusion criteria: During online 
searches of the data, inclusion criteria included papers 
on COVID-19 that focus on human coronavirus 
diseases, epidemiology, laboratory diagnosis, RT-PCR 
test, and additional routine laboratory tests. Articles 
dealing with COVID-19 in relation to animal-to-human 
transmission, disease virology and detailed 
immunological features, the imaging diagnostic 
method, RT-PCR methods only, and papers that focus 
on specific groups (such as diabetes patients, 
hypertension and cardiac patients, and cancer patients) 
were excluded from the analysis.  
 
Data extraction: Data extraction used in the present 
study was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist (12). The eligibility of 
each selected paper for the study was assessed based on 
its publication title, publication period, abstract, 
background, objective and methodology, and results. 
During each analysis, basic inclusion and exclusion 
criteria were used to assess whether the article was 
appropriate to include in the present study. Finally, 
from a total of 75 research articles examined, 29 were 
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Clinical chemistry tests: In most COVID-19 infection, 
RT-PCR test confirmed cases, routine clinical 
chemistry tests were performed to assess liver, renal, 
and cardiac functions. Among these organ function 
tests, aspartate transaminase (AST), alanine 
transaminase (ALT), total and direct bilirubin, and 
albumin were included under liver function tests; 
whereas troponin, creatine kinase muscle-brain 
isoenzymes  (CK-MB), lactate dehydrogenase (LDH) 
and ALT were included under cardiac function tests. In 
addition, urea and creatinine were mentioned as 
markers for renal function tests, and laboratory tests 
such as ferritin and others indicators were sometimes 
included, depending on the specific disease condition 
of COVID-19 cases.  
 
Among the liver function tests, except albumin, all 
other panel test values increased in most COVID-19 
cases. On the other hand, patients with COVID-19 
indicated high values of creatinine in renal function 
tests, as well as high values of CK-MB, troponin and 
LDH in cardiac function tests. The picture of routine 
clinical chemistry tests is summarized in Table 1. 
 
 
Table 1: List of routine clinical chemistry tests with abnormal findings during COVID-19 infection 







Albumin 3.4-5.4 g/dL Decreased 13,14 
Lactate dehydrogenase (LDH) 140-280 IU/L Increased 13,14,15 
Alanine aminotransferase (ALT) Below 40 IU/L Increased 13,14,15.16 
Aspartate aminotransferase (AST) Below 40 IU/L Increased 13,14,15,16 
Total bilirubin Below 2 mg/dl Increased 13,14,15 
Creatinine Below 1.5 mg/dl Increased 13,14,15 
Cardiac troponin (Troponin T) 0-14 ng/ml Increased 13,14,15 
Ferritin 30-400 ng/ml Increased 13,14 
CK-MB 0-25 IU/L Increased 16 
75 articles relating to COVID-19 laboratory 
diagnosis selected using online search 
17 articles excluded, as they deal only 
with RT-PCR and possible transmission 
route 
29 articles selected for review 
6 articles excluded, as they deal with 
virological features of COVID-19  
5 articles excluded, as they deal with 
immunological features of COVID-19  
 
14 articles excluded, as they deal with 
COVID-19 and specific diseases, such as 
diabetes mellitus and cancer 
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Hematology/immunohematology tests: The 
hematology/ immunohematology routine test profile 
of COVID-19 cases were also summarized. Most 
papers indicated that COVID-19 positive cases had 
leukocytosis with an increased number of neutrophils 
and decreased lymphocyte count. In addition, 
prothrombin time (PT) values were increased with 
decreased platelet count results. Besides, 
inflammatory markers, including CRP and ESR 
values were increased in most observations. Among 
the routine immunohematology tests, both CD4 and 
CD8 T-cell counts were decreased. A summary of 
hematology/immunohematology profiles is shown in 
Table 2. 
 
Table 2: List of routine hematology/ immunohematology tests with abnormal findings  










Total WBC count 4,000-10,000/mm3 Increased  13,14 
Decreased 16 
Lymphocyte count 20-35% Decreased 13,14,16,17 
Neutrophil count 40-75% Increased 13,14 
Platelet count 150,000-
400,000/mm3 
Decreased  13,14,16 
Prothrombin time (PT) 10-12 seconds Increased 13,14 
High sensitive C-reactive protein 
(hsCRP) 
Up to 1.5 mg/L Increased 13,14,16 




CD8 200-800cells/mm3 Decreased 17 
 
Thus, this disturbance of the hematology and 
immunohematology profiles in COVID-19 cases may 
result in hyper-inflammatory condition, as indicated by 
the neutrophil‐to‐lymphocyte (109/L) ratio (NLR) and 
lymphocyte (number/μL)/‐to‐C‐reactive protein 
(mg/dL) ratio (LCR). Accordingly, in COVID-19 
disease progression, there will be increased NLR levels 
and low LCR levels, which indicate an enhanced 
inflammatory process (18).  
 
Discussion 
The present systematic study assesses the profiles of 
supportive laboratory tests of COVID-19 RT-PCR-
confirmed cases using routine clinical chemistry and 
hematology/immunohematology test parameters.  The 
study findings indicate that for COVID-19-positive 
cases, from routine clinical chemistry tests, such as 
liver function tests, aminotransferase and lactate 
dehydrogenase enzymes increased; while albumin 
decreased; in renal function tests, creatinine increased; 
and among cardiac markers, CK-MB, troponin and 
ferritin markedly increased. 
  
A study conducted by Petrosillo et al., which compares 
the clinical chemistry aminotransferase enzymes of 
different coronaviruses, indicates an average increment 
value up to 31.5% in COVID-19 cases, whereas these 
enzyme values decreased in cases of SARS and MERS, 
to 23% and 25.5%, respectively (19). On the other 
hand, hypoalbuminemia results shown during COVID-
19 infections were similar in cases of SARS infection 
(20). The increment of aminotransferase enzymes may 
be associated either with cardiac problems associated 
with COVID-19, where AST together with CK, LDH 
and troponin could be high; or in the case of SARS-
CoV-2, virus migration in the intestines and blood may 
infect the liver and damage hepatocytes, which could 
increase ALT, AST and bilirubin values (21). These 
abnormal liver function test results may be seen in up 
to half of patients with COVID-19 infection. Studies 
also indicates that those with pre-existing liver disease, 
and older patients, are at risk of severe liver injury 
(22). Similarly, in COVID-19 positive patients, the 
presence of previous chronic cardiac and renal 
diseases, as well being the patients aged, will 
contribute more for abnormal cardiac and renal 
function tests results. 
 
Thus, the mild to severe increase in aminotransferase 
values and decreased albumin values (23), as well as 
increased routine renal and cardiac function test results, 
might be considered as suggestive of suspected cases 
of COVID-19 infection. 
 
On the other hand, from hematology and 
immunohematology tests, the present analysis indicates 
that the WBC count increased, with decreased 
lymphocytes and increased neutrophil count. In 
contrast, in the case of MERS, and H1N1 infections the 
WBC count decreased up to 14% and 65%, 
respectively (19, 24). However, similar to COVID-19 
cases, very low lymphocyte counts observed in SARS 
and MERS cases (19). In the case of COVID-19, 
occurrences of leukocytosis with neutrophilia and 
lymphopenia may be associated with bacterial infection 
(11). 
 
The present study also indicates that during COVID-19 
infection, platelet count decreased with an increase in 
PT time. Other similar studies also indicate that 
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thrombocytopenia is seen up to 12% in COVID-19 
cases (18) and is relatively high in MERS patients too 
(25). On the other hand, other studies report decreased 
platelet counts in the case of SARS and MERS, up to 
44.8% and 36%, respectively (18,19). Low platelet 
count and high PT time, in the case of COVID-19 
infections, may indicate the severity of infection 
(26,27). 
 
In terms of inflammatory markers, this paper indicates 
that CRP and ESR values increased, with decreased 
CD4 and CD8 counts. The presence of high neutrophil 
count and high CRP values with low lymphocyte 
numbers in COVID-19 positive individuals will create 
increased NLR and decrease LCR values (18). In our 
study, monocyte values did not differ from normal 
values in the case of COVID-19, whereas marked 
monocytosis is seen in the case of MERS (28).  
 
On the other hand, the increased number of neutrophils 
in the case of COVID-19, as seen in this study, might 
be associated with the formation of the neutrophil 
extracellular traps (NETs), as is the case in viral 
influenza virus infection, where the formed NETs 




In conclusion, individuals with signs and symptoms of 
COVID-19 mostly show abnormal results in routine 
hematology and immunohematology tests, such as high 
WBC count, high NLR and low LCR. In addition, 
individuals infected with COVID-19 show 
abnormalities in clinical chemistry tests, summarized 
as mild increases in aminotransferase and creatinine 
values, and increased CK, troponin and ferritin levels. 
  
These routine laboratory clinical chemistry and 
hematology/immunohematology abnormal test results 
might be considered as “supportive and/or suggestive 
test for COVID-19 infection”, and may assist in the 
screening of patients to refer for RT-PCR laboratories 
for confirmation tests and better management of cases.  
 
These “supportive and suggestive routine laboratory 
tests during COVID-19 infections”, in the absence of 
RT-PCR laboratories, might consider as suggestive of 
suspected cases of COVID-19 infection. To strengthen 
this systematic review, additional large-scale studies 
are needed in line with new episodes of the disease. 
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